TNF inhibitor use associated with granulomatous infectious disease; infliximab poses greatest risk

News
Article

Tumor necrosis factor (TNF) antagonists increase the risk of granulomatous infectious disease, including tuberculosis, according to a study-the largest of its kind to date-published in the journal Clinical Infectious Diseases. The risk of infection was 3.25-fold greater among patients who received infliximab (Remicade, Centocor) than among those who received etanercept (Enbrel, Wyeth/Amgen), the study found.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.